Clinical Trial Update: A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 trial evaluating YM155 plus docetaxel in unresectable or metastatic melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Taxotere (docetaxel)
• YM155 (Sepantronium bromide)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Melanoma | Phase 2 | Status: COMPLETED